These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23475565)

  • 1. Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells.
    Hardtke-Wolenski M; Fischer K; Noyan F; Schlue J; Falk CS; Stahlhut M; Woller N; Kuehnel F; Taubert R; Manns MP; Jaeckel E
    Hepatology; 2013 Aug; 58(2):718-28. PubMed ID: 23475565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirements and challenges of a preclinical autoimmune hepatitis mouse model.
    Hardtke-Wolenski M; Noyan F; Jaeckel E
    Dig Dis; 2011; 29(4):402-10. PubMed ID: 21894011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development.
    Hardtke-Wolenski M; Dywicki J; Fischer K; Hapke M; Sievers M; Schlue J; Anderson MS; Taubert R; Noyan F; Manns MP; Jaeckel E
    J Autoimmun; 2017 Mar; 78():39-45. PubMed ID: 27974250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens.
    Lapierre P; Djilali-Saiah I; Vitozzi S; Alvarez F
    Hepatology; 2004 Apr; 39(4):1066-74. PubMed ID: 15057911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different sites of xenoantigen delivery lead to a virally induced late-onset hepatitis in mice through molecular mimicry.
    Piché C; Béland K; Lapierre P; Massie B; Alvarez F
    Liver Int; 2011 Oct; 31(9):1306-14. PubMed ID: 22093453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis.
    Zierden M; Kühnen E; Odenthal M; Dienes HP
    Gastroenterology; 2010 Sep; 139(3):975-86, 986.e1-3. PubMed ID: 20639127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6.
    Hintermann E; Ehser J; Bayer M; Pfeilschifter JM; Christen U
    J Autoimmun; 2013 Aug; 44():49-60. PubMed ID: 23809878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune hepatitis experimental model based on adenoviral infections.
    Lapierre P; Béland K; Alvarez F
    Hepatology; 2014 Jan; 59(1):354. PubMed ID: 23729222
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of autoimmune hepatitis.
    Vergani D; Mieli-Vergani G
    Pediatr Transplant; 2004 Dec; 8(6):589-93. PubMed ID: 15598331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis.
    Czaja AJ; Manns MP
    Gastroenterology; 2010 Jul; 139(1):58-72.e4. PubMed ID: 20451521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse models for experimental autoimmune hepatitis: limits and chances.
    Hardtke-Wolenski M; Jaeckel E
    Dig Dis; 2010; 28(1):70-9. PubMed ID: 20460893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis.
    Ehser J; Holdener M; Christen S; Bayer M; Pfeilschifter JM; Hintermann E; Bogdanos D; Christen U
    J Autoimmun; 2013 May; 42():39-49. PubMed ID: 23200317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling.
    Kido M; Watanabe N; Okazaki T; Akamatsu T; Tanaka J; Saga K; Nishio A; Honjo T; Chiba T
    Gastroenterology; 2008 Oct; 135(4):1333-43. PubMed ID: 18651994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation.
    Yuksel M; Wang Y; Tai N; Peng J; Guo J; Beland K; Lapierre P; David C; Alvarez F; Colle I; Yan H; Mieli-Vergani G; Vergani D; Ma Y; Wen L
    Hepatology; 2015 Nov; 62(5):1536-50. PubMed ID: 26185095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply: To PMID 23475565.
    Hardtke-Wolenski M; Manns MP; Jäckel E
    Hepatology; 2014 Jan; 59(1):354-5. PubMed ID: 23729194
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoimmune hepatitis, from mechanisms to therapy.
    Manns MP; Vogel A
    Hepatology; 2006 Feb; 43(2 Suppl 1):S132-44. PubMed ID: 16447290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budesonide for the treatment of autoimmune hepatitis.
    Snider KR; Potter TG
    Ann Pharmacother; 2011 Sep; 45(9):1144-50. PubMed ID: 21878659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune hepatitis: evolving concepts.
    Diamantis I; Boumpas DT
    Autoimmun Rev; 2004 Mar; 3(3):207-14. PubMed ID: 15110233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome.
    Efe C; Ozaslan E; Kav T; Purnak T; Shorbagi A; Ozkayar O; Berlot AH; Sökmensuer C; Muratori P
    Autoimmun Rev; 2012 Mar; 11(5):330-4. PubMed ID: 22001521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune hepatitis, HLA and extended haplotypes.
    Oliveira LC; Porta G; Marin ML; Bittencourt PL; Kalil J; Goldberg AC
    Autoimmun Rev; 2011 Feb; 10(4):189-93. PubMed ID: 20933106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.